| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Gross profit | 785 | 589 | 607 | 713 |
| Research and development | 97 | 93 | 89 | 92 |
| Marketing and selling | 256 | 206 | 220 | 272 |
| General and administrative | 125 | 132 | 131 | 128 |
| Interest expense, net of capitalized interest | 57 | 80 | 52 | 48 |
| Other expense, net | -9 | 4 | 0 | -11 |
| Income tax expense (benefit) | 30 | 17 | -16 | 14 |
| Total other significant segment expenses | 574 | 524 | 476 | 565 |
| Other expenses | 154 | 341 | 165 | 137 |
| Net income | 57 | -276 | -34 | 11 |
| Depreciation and amortization | 172 | 174 | 176 | 169 |
| Goodwill impairment | NaN | 0 | NaN | NaN |
| Deferred income taxes | NaN | -134 | NaN | NaN |
| Stock-based compensation expense | 21 | 16 | 17 | 20 |
| Asset impairment and write-down charges | NaN | 47 | 24 | 0 |
| Gain on divestiture | NaN | 0 | 0 | NaN |
| Proceeds from interest rate swap settlements | NaN | 0 | NaN | NaN |
| Sold portion of royalty revenue | 9 | 9 | 6 | 4 |
| Interest on liability for sale of future revenue | 14 | 13 | 13 | 7 |
| Changes in operating assets and liabilities, net of divestitures | 524 | NaN | -266 | 5 |
| Other non-cash operating activities, net | 21 | 52 | -30 | -18 |
| Receivables | NaN | 12 | NaN | NaN |
| Inventories | NaN | 57 | NaN | NaN |
| Other assets | NaN | -21 | NaN | NaN |
| Accounts payable and other liabilities | NaN | 147 | NaN | NaN |
| Net cash provided by (used for) operating activities | 13 | 108 | 219 | 237 |
| Net purchases of property and equipment and software | 51 | 62 | 92 | 57 |
| Cash paid for acquisitions | NaN | 0 | NaN | NaN |
| Proceeds from divestitures | 0 | 0 | 0 | 0 |
| Other investing activities, net | 9 | 2 | 9 | -1 |
| Net cash used for investing activities | -60 | -64 | -101 | -56 |
| Proceeds from facility-Revolving Credit Facility | 0 | 0 | 0 | 0 |
| Repayments of facility-Revolving Credit Facility | 0 | 0 | 0 | 0 |
| Proceeds from facility-Securitization Facility | 0 | 0 | 0 | 0 |
| Repayments of facility-Securitization Facility | 0 | 0 | 0 | 85 |
| Proceeds from issuance of long-term debt | NaN | 2,106 | 0 | NaN |
| Repayments of long-term borrowings | 16 | 2,107 | 188 | 361 |
| Proceeds from sale of future revenue, net of transaction costs | NaN | 0 | 0 | 290 |
| Shares repurchased for employee tax withholdings | 34 | NaN | NaN | NaN |
| Other financing activities, net | -15 | -17 | 35 | 0 |
| Net cash (used for) provided by financing activities | -65 | -18 | -153 | -156 |
| Effect of exchange rate changes on cash and cash equivalents | -5 | 14 | 1 | 27 |
| Net (decrease) increase in cash and cash equivalents | -117 | 40 | -34 | 52 |
| Cash and cash equivalents beginning of period | 545 | 505 | 539 | 487 |
| Cash and cash equivalents end of period | 428 | 545 | 505 | 539 |
Elanco Animal Health Inc (ELAN)
Elanco Animal Health Inc (ELAN)